• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Korea·Healthcare·003120.KS
Share

Ilsung Is Co., Ltd. Stocks

₩ 20500Last Updated 23.07.2026

Issuer Rating

3/7
Performance

Average

Risk

Considerable

Recommendation

Sell

Market Cap

₩ 96.45M

₩ 20500
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Solid dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Founded in 1954, Ilsung Pharmaceuticals Co., Ltd. operates as a key pharmaceutical firm in South Korea, headquartered in Seoul. The company specializes in the development and distribution of a comprehensive range of medicinal products. Its extensive portfolio includes antibacterial agents, pain management drugs, muscle relaxants, anticoagulants, various cardiovascular and circulatory system treatments, diagnostic contrast agents, diabetes therapies, gastrointestinal medicines, antiviral compounds, anti-emetic medications, respiratory care solutions, anesthetics, and antipyretics.

Company Valuation

Fairly valued
4/7

Based on key historical and expected multiples, the stock is fairly valued relative to its peers. In particular, the stock is trading at neutral levels on P/FCF.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

23.07.2026 13:00

No Longer a “Black Swan”: Analysts Are Once Again Discussing a Scenario of $150 Oil

23.07.2026 11:29

Nebius shares surged: Google has decided to lease more capacity. Who else stands to benefit?

23.07.2026 10:19

Top Stories This Morning: Oil Prices Surpass $96, CXMT's Record-Breaking IPO, and Big Tech Earnings Reports

23.07.2026 07:00

Reddit shares fell 8% following reports of a possible breakup of its AI partnership with Google

23.07.2026 05:24

Samsung Unveiled New Foldable Smartphones Ahead of Apple's Expected Entry into This Market

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026